FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.

Abstract excerpt

Therapy targeting specific somatic mutations has become an increasingly important part of cancer therapy over the past 20 years. In particular, tyrosine kinase inhibitors (TKIs) have become a critical component of treatment for both solid tumors and hematologic malignancies. Since mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are relatively common in acute myeloid leukemia (AML), activating mutations in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Design
• Share to fms-Like Tyrosine Kinase 3
• Share to FLT3 gene